Femasys Inc. (FEMY)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 |
| Operating profit | $m | -18 | -18 | ||||||
| Net profit | $m | -7 | -8 | -11 | -14 | -19 | -19 | -12 | -5 |
| EPS reported | $ | -9.40 | -4.57 | ||||||
| Operating cashflow per share | $ | -9.45 | -5.28 | ||||||
| Capex per share | $ | 0.27 | 0.14 | ||||||
| FCF per share | $ | -9.72 | -5.42 | ||||||
| Free cash flow | $m | -19 | -18 | ||||||
| Net debt | $m | -6 | 2 | ||||||
| Book value equity | $m | 6 | 4 | ||||||
| Book value per share | $ | 2.97 | 1.20 | ||||||
| Number of shares | m | 1.98 | 3.36 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.88 | 5.65 | ||||||
| P/S LTM | x | 9.93 | 9.91 | ||||||
| P/FCF LTM | x | -1.19 | -1.26 | ||||||
| EV/EBITDA LTM | x | -1.15 | -1.87 | ||||||
| EV/Sales LTM | x | 7.94 | 4.46 | ||||||
| Earnings Yield LTM | % | -81.77% | -1.54% | ||||||
| FCF Yield | % | -84.35% | -79.54% | ||||||
| Quality | |||||||||
| ROE | % | -317.38% | -216.46% | ||||||
| ROIC | % | -1.00% | +13.35% | ||||||
| Operating margin | % | -7.67% | -7.64% | ||||||
| Gross margin | % | +61.96% | +50.48% | ||||||
| FCF/Sales | % | -837.90% | -788.00% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +40.77% | +41.15% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -4.09 | -3.78 | ||||||
| Net Debt/EBITDA | x | 0.29 | -0.33 | ||||||
| EBIT/Net interest | x | -9.30 | -30.42 | ||||||
| Net debt/market cap | % | +13.95% | +69.28% | ||||||
| Net debt/Equity | x | -1.04 | 0.52 | ||||||
| Gross debt/equity | x | 0.80 | 1.19 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free